Acadia Pharmaceuticals Inc. (ACAD)
ACADNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$18.67
+0.1990 (+1.08%) today
At the close, Nov 16, 4:00 PM ET. Pre-market $18.49 -0.96%
- Market cap
- $3.20bn
- P/E
- 27.9
- EPS, last 4 quarters
- $0.6700
- Dividend yield
- –
- Day range
- –
- 52-week range
- $15.86 to $30.96
- Average volume
- –
- Previous close
- $18.47
Analysts
14 coveringBuy10 buy, 4 hold, 0 sell
Targets a year out average $31.43, +68.3% from here
Earnings
next estimate $0.2800Next report
Dec 2025
+33.3%
Mar 2026
-50.0%
Jun 2026
+200.0%
Sep 2026
+63.2%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $283.99m | $268.06m | $307.96m | $342.29m |
| Gross profit | $257.76m | $243.27m | $279.64m | $307.20m |
| Operating income | $17.39m | -$4.62m | $37.84m | $71.72m |
| Net income | $273.57m | $3.64m | $31.50m | $53.52m |
Last four quarters: revenue $1.20bn, margin 30.1%, free cash flow $81.99m
News
8 latest- Acadia Expands Rett Syndrome Partnership In Japan Through KYORIN Agreement RTTNews · 20 hours ago
- Acadia Reveals Federal Circuit Hearing Of Nuplazid Patent Appeal, Ruling Expected In H1 2027 RTTNews · Nov 10, 2026
- Acadia Pharmaceuticals Enters Oversold Territory (ACAD)BNK Invest · Nov 9, 2026
- Acadia Pharma (ACAD) Q3 2026 Earnings Call TranscriptThe Motley Fool · Nov 5, 2026
- What ACADIA Pharmaceuticals (ACAD) Said on Its Q3 Earnings CallMarketBeat · Nov 4, 2026
- Acadia Pharmaceuticals (ACAD) Tops Q3 Earnings and Revenue EstimatesZacks · Nov 4, 2026
- Viatris Gears Up to Report Q3 Earnings: Is a Beat in the Cards?Zacks · Nov 3, 2026
- Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Tops Revenue EstimatesZacks · Nov 2, 2026
The company
Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we're here to be their difference.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- acadia.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.